| Name | Title | Contact Details |
|---|
HealthLoop automates patient engagement to help health providers reduce cost, improve outcomes and deliver a 5-star patient experience. Reassuring guidance each step of the way connects care teams with patients who need it most. HealthLoop enables value-based care for hospitals to monitor at-risk populations, provide outreach when most needed and track patients through an episode of care. Patients rate their doctors with a 5-star experience and providers realize better efficiencies with an automated patient check-in approach. Located in Mountain View, HealthLoop facilitates over 25,000 automated check-ins each month.
As a nonprofit engineering innovation company, Draper serves our nation`s interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers` needs and to deliver new capabilities to them.
Improving lives by enhancing precision cancer diagnostics.
PolarityTE, is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients` own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient`s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.
Cortendo AB is a global biopharmaceutical company founded in 1996, incorporated in Sweden, and based in the United States. Cortendo recognizes the urgent need to make new medicines available for people with orphan diseases, and the Company is committed to delivering therapies that make a difference. An orphan disease is one for which the pharmaceutical industry has not worked to make new medicines. It may be a rare disease (in the U.S. this is defined as a disease that affects fewer than 200,000 people) or a disease such as tuberculosis, cholera, typhoid or malaria that is not often diagnosed in developed countries but remains common in countries that are still developing. Cortendo’s initial strategic goal is to be the global leader in finding, developing and making medicines for people with orphan endocrine diseases, with its most advanced program in Cushing’s syndrome. Cortendo research led to the development of COR-003 (levoketoconazole) which is currently being studied in the Phase 3 global SONICS trial for the treatment of endogenous Cushing’s syndrome. COR-003 has received orphan designation from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Cortendo is building the capabilities and resources to independently develop and commercialize its orphan assets in key global markets and to partner non-strategic product opportunities, such as BioPancreate-2001 for Type 1 and Type 2 diabetes. The company also intends to leverage its commercial expertise by working with partners to acquire, develop, and commercialize late-stage or commercial assets in a select few orphan disease focus areas.